OSE Immunotherapeutics is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer. This appointment follows... View Article
Author Archives for Adeline Chauvigné
OSE Immunotherapeutics appoints Nicolas Poirier as Chief Executive Officer
6 May 2024OSE Immunotherapeutics is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer. This appointment follows... View Article
Valneva raises more than 100 million euros
The financing was led by US healthcare specialist Deep Track Capital and also included existing shareholders such as French state-owned... View Article
Valneva raises more than 100 million euros
6 May 2024The financing was led by US healthcare specialist Deep Track Capital and also included existing shareholders such as French state-owned... View Article
The biotechnology company HEMARINA obtains the CE mark for its HEMO2life® technology
A major breakthrough innovation for organ transplants Thanks to the CE marking obtained for its additive to organ preservation solutions... View Article
The biotechnology company HEMARINA obtains the CE mark for its HEMO2life® technology
6 May 2024A major breakthrough innovation for organ transplants Thanks to the CE marking obtained for its additive to organ preservation solutions... View Article
Our Belgian partners host the Bioregate Forum for the first time
After two editions in Nantes, Bioregate Forum, the European Regenerative Medicine Forum, took on a European dimension. It was in Louvain-la-Neuve, Belgium, that the highlight of... View Article
Our Belgian partners host the Bioregate Forum for the first time
6 May 2024After two editions in Nantes, Bioregate Forum, the European Regenerative Medicine Forum, took on a European dimension. It was in Louvain-la-Neuve, Belgium, that the highlight of... View Article
BioMAdvanced Diagnostics raises €1,7 million
The investment to be used to develop its diagnostics solutions and contribute to improving the life of patients having received... View Article
BioMAdvanced Diagnostics raises €1,7 million
6 May 2024The investment to be used to develop its diagnostics solutions and contribute to improving the life of patients having received... View Article
Valneva provides further update on its COVID-19 activities
Valneva, a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities. The company had previously communicated... View Article
Valneva provides further update on its COVID-19 activities
6 May 2024Valneva, a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities. The company had previously communicated... View Article
Pherecydes Pharma successfully completes €3.1 million capital increase
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the... View Article
Pherecydes Pharma successfully completes €3.1 million capital increase
6 May 2024Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the... View Article
Same™ by i-SEP medical device has obtained the CE mark and started marketing
i-SEP announces the CE marking and marketing of its autotransfusion medical device: same™ by i-SEP. For the past several months... View Article
Same™ by i-SEP medical device has obtained the CE mark and started marketing
6 May 2024i-SEP announces the CE marking and marketing of its autotransfusion medical device: same™ by i-SEP. For the past several months... View Article
Biofortis is part of the national project Le French Gut, to accelerate the science of the microbiota
READ THE PRESS RELEASE Biofortis as a unique full service CRO providing Nutrition Clinical Trials, Microbiome Investigation and Data Science... View Article
Biofortis is part of the national project Le French Gut, to accelerate the science of the microbiota
6 May 2024READ THE PRESS RELEASE Biofortis as a unique full service CRO providing Nutrition Clinical Trials, Microbiome Investigation and Data Science... View Article
Perha Pharmaceuticals is a laureate of the European Innovation Council (EIC) Accelerator Programme and could receive an €8 M in funding for the development of its lead candidate Leucettinib-21
Perha Pharmaceuticals has been selected by the European Commission under the European Innovation Council (EIC) Accelerator Programme for the development... View Article
Perha Pharmaceuticals is a laureate of the European Innovation Council (EIC) Accelerator Programme and could receive an €8 M in funding for the development of its lead candidate Leucettinib-21
6 May 2024Perha Pharmaceuticals has been selected by the European Commission under the European Innovation Council (EIC) Accelerator Programme for the development... View Article